BC Week In Review | Mar 14, 2019
Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BC Innovations | Feb 2, 2017
Distillery Therapeutics


INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting ROR1 or the long non-coding RNA (lncRNA) MAYA could help treat bone-metastatic breast cancer. In a bone-metastatic human breast cancer line, ROR1 knockout or MAYA...
BioCentury | Oct 24, 2016
Emerging Company Profile

RORing against resistance

  Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. The Bruton’s tyrosine kinase...
BC Week In Review | Jun 6, 2016
Company News

Oncternal, Tokalas deal

Cancer companies Oncternal and Tokalas merged and will retain the Oncternal name. Oncternal’s cirmtuzumab (UC-961), a humanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1), is in Phase I testing to treat relapsed...
Items per page:
1 - 5 of 5